Dietary supplement allergy claims
This article was originally published in The Tan Sheet
Executive Summary
San Clemente, Calif.-based Metagenics will no longer dispute FDA's contention that the statements "promotes a healthy immune response in people who may be sensitive to environmental substances" and "promotes healthy histamine levels" are disease claims. FDA first flagged four structure/function claims for the allergy supplement Perimine in a March 2003 "courtesy letter." The firm argued allergies do not constitute a disease state because they are not "damage to an organ, part, structure or system of the body such that it does not function properly, or a state of health leading to such dysfunctioning." FDA disagreed, maintaining "an allergic response is, in fact, unambiguously a consequence of damage to a system (the immune system) such that it does not function properly in that it is hypersensitive to allergens." The agency adds that the claims cannot be modified so that they are not disease claims...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.